India, March 31 -- image credit- shutterstock

AI may be the buzzword of the moment, but in reality it represents a structural shift rather than a standalone technology. It is emerging as an enabling layer across the pharmaceutical value chain - from drug discovery and clinical development to manufacturing and patient engagement.

While AI is widely touted as transformative for the pharma industry, its adoption is not without caveats. There are several ifs and buts around data quality, regulatory expectations, integration with legacy systems, talent readiness, validation standards, and cultural acceptance. The promise is significant, but real impact will depend on how thoughtfully and responsibly the technology is implemented.

On the sid...